Quantcast

Latest TWi Biotechnology Inc. Stories

2014-10-21 08:34:45

TAIPEI, Oct. 21, 2014 /PRNewswire/ -- TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Orphan Drug by US FDA for using AC-201 to treat epidermolysis bullosa (EB). TWi Biotechnology has developed proprietary formulations to be used topically for the indication of EB. "We are very pleased with the approval of orphan drug designation for treating epidermolysis bullosa. It fulfills the mission of our new...

2011-06-14 04:00:00

TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center study is primarily designed to evaluate the glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 in patients with Type II Diabetes Mellitus. Meanwhile, the cardiovascular...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related